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novel	 interventions.	A	greater	understanding	of	 the	general	 evolutionary	principles	
that	are	at	the	core	of	emerging	resistance	 is	urgently	needed	if	we	are	to	develop	
improved	 resistance	 management	 strategies	 with	 the	 ultimate	 goal	 to	 achieve	 a	
malaria-	free	world.




The	 Global	 Technical	 Strategy	 for	 Malaria	 2016–2030	 envisions	 a	
world	free	of	malaria	and	sets	ambitious	targets	to	(i)	reduce	malaria	
incidence	and	mortality	rates	globally	by	at	least	90%	by	2030,	(ii)	elim-
inate	 the	 disease	 in	 at	 least	 35	 new	 countries	 (as	 of	 2015)	 and	 (iii)	
prevent	its	re-	establishment	in	countries	that	were	free	of	malaria	in	
2015	(World	Health	Organization,	2015a).	The	strategy	builds	on	the	










and	 South-	East	 Asia	 (SEA)	 are	 now	 aiming	 for	 malaria	 elimination.	
Their	elimination	efforts	continue	to	rely	heavily	on	antimalarial	drugs	
and	 insecticides,	 our	 front-	line	 interventions.	 But	will	 these	 remain	
effective	 as	 parasites	 and	 mosquitoes	 respond?	 Recent	 years	 have	
seen	malaria	detection	(Gamboa	et	al.,	2010;	Kozycki	et	al.,	2017)	and	
treatment	failures	(Dondorp	et	al.,	2009;	Imwong	et	al.,	2017)	due	to	
evolving	 parasites	 and	 alarmingly	 decreases	 in	 insecticide	 suscepti-
bility	 due	 to	 evolving	mosquitoes	 (Hemingway,	Ranson	 et	al.,	 2016;	
Ranson	&	Lissenden,	2016).	This	so-	called	evolutionary	arms	race	(i.e.,	
competition	 between	 coevolving	 species	 that	 develop	 adaptations	
and	counter-	adaptations	against	each	other)	between	human	 (host),	
mosquito	(vector)	and	malaria	(parasite)	must	have	occurred	since	the	
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day	they	interacted.	Evidence	for	human	adaptation	to	malaria	para-
sites	are	for	instance	sickle-	cell	and	glucose-	6-	phosphate	dehydroge-
nase	deficiency	 (G6PD)	 genes	 in	 certain	populations	 living	 in	highly	
endemic	 malaria	 areas	 (Luzzatto,	 Usanga,	 &	 Reddy,	 1969;	 Pauling,	
Itano,	Singer,	&	Wells,	1949).




insecticides	 and	 larvicides.	However,	 both	 parasite	 and	vector	 have	
evolved	 a	 large	 variety	 of	 countermeasures	 to	withstand	 or	 endure	
our	 interventions.	As	 a	 consequence,	we	 are	 now	 forced	 to	 rapidly	








and	 chemical	 industries	 keep	 investing	 in	 compound	 development.	
This	may	especially	be	true	when	we	get	closer	to	elimination:	when	
a	 novel	 chemistry	 is	 needed	 after	 significant	 reductions	 in	 disease	
burden	have	been	achieved,	there	is	almost	certainly	no	financial	in-


















and	mosquitoes	 is	 a	 result	 of	 simple	Darwinian	principles	of	 fitness	
costs/benefits	 in	 the	 presence/absence	 of	 the	 drug	 or	 insecticide.	
When	the	failure	of	malaria	 interventions	 is	seen	as	an	evolutionary	
process,	that	is,	the	outcome	of	the	competitive	interactions	between	
wild-	type	 (susceptible)	 and	 mutant	 (resistant)	 organisms,	 resistance	












the	current	 front-	line	 intervention	strategies	 for	both	mosquito	and	
parasite	and	the	current	status	of	the	evolutionary	adaptations	in	both	
organisms.
2.1 | Targeting the mosquito vector
Reducing	the	vector	population	size	is	an	effective	method	in	malaria	
control.	 The	 main	 front-	line	 vector	 control	 interventions	 are	 long-	












Indoor	 residual	 spraying	 is	 believed	 to	 have	 prevented	 roughly	
66	million	clinical	cases,	contributing	to	13%	of	the	overall	reduction	
in	 disease	 prevalence	 between	 2000	 and	 2015	 (Bhatt	 et	al.,	 2015).	
Although	for	IRS	three	additional	classes	of	insecticides	are	available	





The	 success	 of	 these	 chemical	 interventions	 is	 related	 to	 the	
quantities	being	distributed	and	used:	since	2010,	close	to	1.2	billion	
pyrethroid-	based	bed	nets	have	been	distributed,	of	which	1	billion	








represented	a	major	 selection	pressure	 for	DDT	and,	more	 recently,	
pyrethroid	 resistance.	Moreover,	 these	 numbers	 exclude	 insecticide	
use	in	the	agricultural	sector	which	most	likely	results	in	an	additional	









resistance	 due	 to	 P450-	mediated	 metabolic	 resistance	 (Toé	 et	al.,	
2014))	and	(ii)	the	need	to	better	predict	the	impact	of	insecticide	re-
sistance	on	malaria	control	 (failure),	other	methodologies	have	been	
introduced	 to	measure	 the	 intensity	 or	 strength	 of	 resistance.	 The	





Biochemical	 and/or	 molecular	 methods	 to	 detect	 resistance	 at	
a	 mechanistic	 level	 can	 also	 be	 powerful	 tools	 for	 screening	 vec-
tor	 populations.	 But	while	 the	 genetic	 changes	 of	 resistant	 vectors	





surveillance	 (Weetman	 &	 Donnelly,	 2015;	 See	 also	 Sternberg	 and	
Thomas,	2017).
2.1.2 | The emergence and spread of 
insecticide resistance















(Coleman	 et	al.,	 2017).	 The	 initial	 wave	 of	 pyrethroid	 resistance	 is	
likely	a	reselection	of	an	old	DDT	resistance	mechanism	in	An. gam-
biae	 (Hemingway,	 2014),	 as	 both	 insecticides	 have	 a	 similar	 mode	
of	action.	As	 the	mutations	 involved	have	arisen	multiple	 times	and	
have	spread	from	different	locations,	we	refer	to	West	or	East	African	
forms	of	kdr,	 indicating	where	 they	were	 first	detected	 (Pinto	et	al.,	
2007).	The	cytochrome	P450-	based	mechanism	 in	An. funestus	 that	
led	 to	 a	>	1,000-	fold	 increase	 in	 resistance	 to	 pyrethroids	was	 first	











2.1.3 | The impact of insecticide resistance on 
malaria transmission
The	 extent	 to	 which	 the	 observed	 widespread	 and	 high	 levels	 of	
insecticide	 resistance	 threaten	 malaria	 control	 and	 elimination	 ef-
forts	remains	unclear	(Rivero,	Vézilier,	Weill,	Read,	&	Gandon,	2010;	
Strode,	 Donegan,	 Garner,	 Enayati,	 &	Hemingway,	 2014;	 Thomas	&	
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Read,	2016).	A	recently	concluded	multicountry	assessment	to	deter-
mine	the	impact	of	insecticide	resistance	on	the	protective	effective-
ness	of	LLINs,	and	 thus	on	malaria	 transmission,	 showed	 there	was	
no	evidence	of	 an	 association	between	malaria	 disease	burden	 and	
pyrethroid	 resistance	 across	 locations	 (World	 Health	 Organization,	
2016a).	There	are,	however,	several	reasons	why	it	may	be	difficult	to	
observe	an	impact	of	resistance:
1. Susceptibility	 tests:	 Insecticide	 susceptibility	 as	 determined	 with	
standard	 bioassays	 may	 not	 reflect	 susceptibility	 under	 actual	
field	 conditions	 as	 such	 tests	 are	 performed	 with	 young	 (2-	 to	
5-day-old)	 female	 mosquitoes	 following	 single,	 limited-time	 ex-
posure	 to	 an	 insecticide	 under	 constant	 insectary	 conditions.	
As	 a	 result,	 the	 effect	 of	 natural	 mosquito	 traits	 such	 as	 sex,	
age,	 blood-feeding	 status	 and	 circadian	 rhythm	 (Kulma,	 Saddler,	
&	 Koella,	 2013;	 Oliver	 &	 Brooke,	 2014)	 but	 also	 climatic	 vari-
ables	 (Glunt,	 Blanford,	 &	 Paaijmans,	 2013)	 on	 the	 toxicity	 of	
insecticides	 is	 not	 captured,	 neither	 are	 sublethal	 effects	 on	
blood-feeding	and	host-seeking	factors	(Glunt	et	al.,	unpublished),	
infection	with	entomopathogens	such	as	Plasmodium	(Alout	et	al.,	
2016),	 or	 delayed	 mortality	 (Viana,	 Hughes,	 Matthiopoulos,	






species	 as	well	 as	 population	 diversity	within	 one	 species	 (Lobo	
et	al.,	2015).
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active	but	not	yet	protected	by	LLINs	(Bayoh	et	al.,	2014;	Moiroux	
et	al.,	 2012;	 Reddy	 et	al.,	 2011;	 Russell	 et	al.,	 2011;	 Sougoufara	
et	al.,	 2014;	 Taylor,	 1975)	 or	 changed	 their	 host	 preference	
(Lefèvre	et	al.,	2009).
4. Parasite–mosquito	 interactions:	 There	 may	 be	 several	 ways	 in	
which	 insecticide	 resistance	 impacts	 parasite	 survival	 inside	 the	
mosquito	hosts.	Pyrethroid	resistance	has	been	demonstrated	to	
reduce	mosquito	survival	following	a	Plasmodium	infection,	possi-
bly	 because	 the	 insecticide-resistant	 alleles,	 or	 closely	 linked	 al-
leles,	 interfere	 with	 the	 immune	 system	 (Alout	 et	al.,	 2016).	 In	
addition,	 field-collected	 kdr	 homozygous	 mosquitoes	 that	 were	
experimentally	infected	with	malaria	and	subsequently	exposed	to	
deltamethrin	 impregnated	 bed	 nets	 showed	 a	 lower	 prevalence	
and	lower	intensity	of	infection	compared	to	infected	mosquitoes	




oratory	setting	 (Alout	et	al.,	2013,	2014)	and	 in	 the	field	 (Kabula	
et	al.,	2016;	Ndiath	et	al.,	2014).	As	such,	the	overall	effect	of	in-
secticide	 resistance	 on	 parasite	 transmission	 is	 still	 unclear,	 yet	
these	studies	highlight	that	vector	control	and	parasite	epidemiol-
ogy	cannot	be	seen	independently.
2.2 | Targeting the malaria parasite




instantly	 be	 selected	upon	 (Gerstein,	Cleathero,	Mandegar,	&	Otto,	










ing,	 e.g.,	 only	 the	 sexual	 stages	 that	 are	 transmitted	 to	mosquitoes,	
such	as	the	gametocytocidal	drug	primaquine),	see	Figure	1.	Several	
antimalarial	drugs	have	been	rolled	out	over	the	past	6	decades,	from	


























for	detecting	 treatment	 failure	 is	 the	 in	vivo	assay	of	parasite–drug	
response	in	malaria	patients,	with	a	follow-	up	time	of	at	least	28	days	
(World	Health	Organization,	2015b).	The	main	problem	with	this	ap-
proach	 is	 that	 “failure”	 could	 be	 caused	 by	 malaria	 recrudescence	
(or	relapse)	or	reinfection,	which	 is	 likely	to	occur	 in	endemic	areas.	
The	molecular	methods	 that	 are	used	 to	distinguish	between	 these	
categories	 are	not	 sensitive	 enough	 (Juliano,	Gadalla,	 Sutherland,	&	
Meshnick,	2010).	Novel	 and	more	 sensitive	methods,	 such	as	next-	
generation	sequencing	to	determine	the	genotype	composition	in	the	













2.2.2 | The emergence and spread of drug resistance
Resistance	of	P. falciparum	parasites	 to	chloroquine,	 the	 first	widely	
available	antimalarial,	started	to	spread	across	the	majority	of	malaria-	
endemic	areas	 in	 the	60s	and	70s.	The	drug	was	replaced	with	sul-
phadoxine–pyrimethamine	 (SP)	as	 the	 first-	line	 treatment	 in	 several	
countries	in	the	90s.	SP	was	used	as	clinical	treatment,	but	also	as	in-
termittent	preventive	treatment	during	pregnancy	(IPTp)	and	infancy	
(IPTi).	After	 resistance	 to	SP	appeared	 in	East	Africa,	 it	 spread	very	
rapidly	across	Africa	 in	 the	90s	and	2000s	 (Naidoo	&	Roper,	2010;	
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Nair	et	al.,	2003).	 IPTi-	SP	 is	 abandoned	 in	all	 areas	with	high	 levels	
of	resistance	(defined	as	a	prevalence	of	the	Pfdhps	540	mutation	of	
>50%),	 but	 IPTp	with	SP	 is	 still	 being	 recommended	 (World	Health	
Organization,	2015b)	and	remains	successful	to	date	despite	the	high	






was	 failing	 in	 the	 Greater	 Mekong	 Subregion	 (GMS)	 (Leang	 et	al.,	
2013;	Saunders,	Vanachayangkul,	&	Lon,	2014).	The	distribution	and	
spread	of	the	different	emerging	mutants	responsible	for	artemisinin	
resistance	were	 almost	 being	 tracked	 in	 real	 time.	 Initially,	multiple	
independent	appearances	of	mutant	PfKelch13	alleles	were	observed.	










and	SP	did	 in	 the	past	 (Figure	3).	This	 success	may	be	attributed	 to	
drug	properties,	as	artemisinins	(i)	act	more	rapidly	and	have	a	shorter	
half-	life	than	all	other	antimalarials,	resulting	 in	a	shorter	window	of	
selection	 (Corey	 et	al.,	 2016),	 and/or	 (ii)	 are	 protected	 by	 a	 partner	
drug	with	 a	 longer	 half-	life,	 so	 selective	 pressure	 is	 always	 for	 two	
drugs	of	different	mode	of	action	at	the	same	time.	However,	despite	
this	 theory,	 resistance	 to	 artemisinin	 arose	 before	 resistance	 to	 the	
partner	drug	in	ACTs	(Imwong	et	al.,	2017),	possibly	due	to	the	history	
of	monotherapy	in	the	area.
A	 highly	 curious	 observation	 in	 the	 evolution	 of	 antimalarial	 re-
sistance	 is	 that	 the	 current	 circulating	mutants,	which	 have	 led	 in-
dependently	 to	 resistance	 to	a	variety	of	drugs,	 seem	 to	have	gone	
through	the	exact	same	process	at	the	exact	same	location:	the	mu-
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GMS	a	breeding	ground	for	resistance	evolution?	Are	the	factors	re-
lated	 to	 the	host,	 the	parasite,	drug	practices	or	are	other	epidemi-
ological	 factors	 such	as	 transmission	 intensity	 responsible?	A	better	
understanding	of	this	resistance	breeding	ground	is	critical	as	it	(i)	may	





2.2.3 | The direct impact of drug resistance on 
parasite fitness
The	 rapid	 pace	 with	 which	 chloroquine-	 and	 SP-	resistant	 parasites	
have	spread	across	the	world	shows	the	selective	advantage	that	re-







even	 completely	 absent	 (e.g.,	 Laufer	 et	al.,	 2010;	 Mekonnen	 et	al.,	
2014;	Mwanza	et	al.,	2016).	A	recent	clinical	trial	with	chloroquine	in	
asymptomatic	adults	in	Mozambique	demonstrated	that	chloroquine	
may	 actually	 be	 effective	 again	 in	 curing	 infected	 patients	 (Galatas	
et	al.,	2017).	However,	 similar	patterns	have	not	been	observed	 for	
SP	resistance	despite	a	reduction	in	drug	use	(Artimovich	et	al.,	2015;	
Kateera	et	al.,	2016).	The	 lack	of	a	 reduction	 in	 frequency	of	 folate	
resistance	markers	under	 the	 reduced	selection	pressure	 is	 striking,	
although	SP	is	still	used	as	preventive	treatment	in	pregnant	women	
(IPTp).	 Nevertheless,	 Artimovich	 et	al.	 (2015)	 even	 observed	 an	 in-
crease	 in	 the	 frequency	of	 triple	pfdhps	mutants	during	a	period	of	
reduced	 SP	 pressure.	One	may	 conclude	 that	 chloroquine-	resistant	
parasites	 perhaps	 carry	 a	 higher	 fitness	 cost	 that	 their	 SP-	resistant	
siblings,	although	direct	evidence	is	lacking.
3  | APPLICATION OF EVOLUTIONARY 





nate	malaria	 if	we	are	able	 to	mitigate	 resistance	evolution.	History	
shows	that	resistance	evolution	is	nearly	always	a	question	of	“when,”	
not	“if.”	As	(i)	drugs	and	insecticides	continue	to	be	a	cornerstone	of	
malaria	 elimination	 strategies,	 (ii)	we	only	 have	 a	 few	options	 (ACT	
with	six	partner	drugs	and	four	insecticide	classes	with	only	two	dif-
ferent	modes	of	action),	which	 (iii)	 start	 to	 fail,	or	have	already	 lost	
efficacy,	and	 (iv)	 it	will	 take	several	more	years	 for	novel	drugs	and	
insecticides	 to	 become	 available	 (Hemingway,	 Shretta	 et	al.,	 2016),	
the	evolutionary	management	of	resistance	will	be	a	critical	compo-
nent	(McClure	&	Day,	2014).	The	main	question	is	whether	resistance	















presence	 of	 the	 toxic	 compound	 (insecticide	 or	 antimalarial	 drug),	
in	 the	absence	of	 treatment	 this	cost	 is	 likely	unaffordable	and	may	












3.1 | Insecticide resistance management strategies
The	WHO	set	out	clear	guidelines	to	manage	 insecticide	resistance	
in	 their	Global	 Plan	 for	 Insecticide	Resistance	Management	 (World	
Health	 Organization,	 2012a).	 They	 urged	 to	 implement	 strategies	
such	 as	mosaic,	 rotational	 or	mixture	 spraying	 regimes	 (IRS),	which	
all	avoid	using	the	same	class	of	chemical	for	longer	periods	of	time,	
hence	reducing	the	selective	pressure	of	resistance	against	one	par-
ticular	 chemical.	 At	 least	 two	 insecticides	 with	 different	 modes	 of	
action	are	used	in	different	but	neighbouring	areas	(mosaic),	rotated	
from	one	year	to	the	next	(rotation)	or	are	mixed	into	a	single	product	






viciding	 (Koella,	 Lynch,	 Thomas,	 &	 Read,	 2009),	 LLINs	with	 attrac-
tive	 toxic	 sugar	baits	 (Stone,	Chitnis,	&	Gross,	2016)	or	LLINs	with	
mosquitocidal	ivermectin	in	humans	or	domesticated	animals	(Pooda	
et	al.,	2015;	Richards,	2017).	Such	an	approach	would	be	particularly	
422  |     HUIJBEN aNd PaaIJMaNS
effective	if	one	such	insecticide	would	force	evolution	in	a	direction	
that	would	make	mosquitoes	more	susceptible	to	the	second	insec-
ticide	 (Koella	 et	al.,	 2009;	 Volkman	 et	al.,	 2017).	 The	 disadvantage	
of	 the	 approaches	 described	 above	 is	 that	 different	 interventions	
in	the	same	package	target	different	mosquito	behaviours	 (e.g.,	bit-
ing,	 resting	and	breeding	behaviours)	 and	may	also	 target	different	
vector	species.	As	such,	vectors	may	only	get	exposure	to	one	inter-





Bourguet,	 &	 Raymond,	 1998;	 Lenormand,	 Bourguet,	 Guillemaud,	
&	Raymond,	1999;	Park,	Haven,	Kaplan,	&	Gandon,	2015).	The	ap-
proaches	 above	 (different	 resistance	management	 strategies	or	 the	
combination	of	different	insecticide-	based	interventions	across	space	
and/or	time)	are	not	novel	as	they	have	for	 long	been	used	in	agri-




tions:	 in	 the	field	of	medicine,	mixing	of	chemicals	 is	common	prac-
tice	 to	 deter	 resistance	 evolution,	 with,	 for	 example,	 combination	
therapy	being	the	norm	for	malaria,	HIV	and	tuberculosis	treatment.	
Monotherapy	 is	 nowadays	 considered	wrong,	 at	 least	 at	 the	 policy	
level,	but	this	thinking	has	surprisingly	not	yet	made	its	way	into	the	
vector	 control	 community.	 Although	 the	 pipeline	 of	 the	 Innovative	










How	frequently	should	 insecticides	be	 rotated?	What	spatial	 scale	 is	
needed	 for	 mosaic	 application?	 The	 answer	 to	 these	 questions	 lies	










scale	 field	 trials	 whereby	 different	 strategies	 are	 evaluated	 will	 be	






suggests	 that	higher	 levels	of	heterogeneity	of	 selection	are	associ-













consider	 resource	 availability,	 practicality	 and	 a	 cost-	benefit	 analysis	
(Hemingway	et	al.,	2013;	World	Health	Organization,	2010,	2012a).











2009;	 Read	 et	al.,	 2009).	 Since	 by	 that	 time	 the	mosquito	will	 have	
completed	 most	 of	 its	 reproductive	 lifespan,	 the	 selective	 pressure	
will	be	greatly	reduced.	One	way	to	create	a	so-	called	late-	life-	acting	
intervention	is	to	use	lower	concentrations	of	existing	insecticides	to	
only	 kill	 the	 older	 and	weaker	mosquitoes	 (Glunt,	 Thomas,	 &	 Read,	








if	 selective	pressure	 is	 acting	on	mosquitoes	 to	 invest	 in	 short-	term	
reproduction	instead	of	long-	term	survival.	Such	life	history	shift	could	
greatly	 reduce	 malaria	 transmission	 (Ferguson	 et	al.,	 2012),	 though	
of	 course,	 an	 evolutionary	 response	 in	 the	 parasite	 population,	 for	
instance	 an	 increased	 developmental	 rate	with	 any	 possible	 conse-
quences	for	parasite	virulence	or	transmission,	should	be	anticipated.
Transmission	 blocking	 approaches	 within	 the	 mosquito	 vector	
avoid	 the	 evolution	 of	 insecticide	 resistance	 using	 compounds	 that	
only	target	the	development	of	the	parasite	within	the	mosquito,	hence	
not	 putting	 pressure	 on	 the	 mosquito	 itself.	 Childs	 and	 colleagues	
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identified	 a	 compound	 that	 manipulates	 the	 steroid	 hormone	
20-	hydroxyecdysone	 (20E)	 pathways,	which,	when	 applied	 to	mos-
quitoes,	 successfully	 disrupts	 parasite	 development.	 Unfortunately,	








to	 increase	 behavioural	 plasticity	 in	 daytime	 or	 night-	time	 feeding,	
possibly	due	to	increased	energy	availability	leading	to	increased	for-




An	 additional	 transmission	 blocking	 method	 is	 based	 on	 the	
maternally	 transmitted	 symbiotic	 bacteria	 of	Wolbachia	 spp.	 which	




selection	for	 resistance	 in	 the	vector,	all	of	 the	above-	described	ap-
proaches	are	of	course	under	selection	from	the	parasite	point	of	view.




will	be	 for	 those	mosquitoes	being	deterred	by	 the	spatial	 repellent	
and	are	 therefore	 avoiding	 (lethal)	 exposure	 to	 the	 insecticide.	As	 a	
consequence,	 this	method	would	protect	 the	 insecticide	 from	 resis-
tance	 evolution	 by	 decreasing	 the	 amount	 of	mosquitoes	 being	 ex-
posed,	as	well	as	driving	selection	towards	 increased	efficacy	of	the	
spatial	repellent,	ensuring	that	mosquitoes	that	are	being	effectively	
repelled	have	a	survival	advantage	 (Lynch	&	Boots,	2016).	 It	has	 in-
deed	been	 shown	with	 a	population	genetics	model	 that	 the	 repel-
lent	 properties	 of	 insecticide-	treated	 bed	 nets	 have	 contributed	 to	







derlying	principles	 to	 retard	 resistance	evolution	are	 clear,	but	 solid	
experimental	(especially	field-	generated)	evidence	is	lacking.
3.2 | Drug resistance management strategies
The	strategy	to	deal	with	the	emerging	ACT	resistance	in	the	Greater	
Mekong	Subregion	is	to	rapidly	eliminate	all	malaria	parasites	 in	the	






proposed	 strategy	 depends	 to	 a	 large	 extent	 on	 the	 very	 drug	 the	
parasites	are	evolving	resistance	to.	Proposed	strategies	are	 (i)	drug	
rotations	with	existing	ACTs	such	as	DHA–PPQ	(currently	failing)	and	
artesunate–mefloquine	 (currently	effective),	 (ii)	 triple	drug	combina-
tions	such	as	DHA–PPQ–mefloquine,	(iii)	extension	of	the	treatment	
course	from	3	to	7	days	or	(iv)	using	the	compound	arterolane–pipe-
raquine	which	 is	new	to	 the	GMS	 (Dondorp	et	al.,	2017).	Major	 re-



































as	quickly	 as	possible.	This	dogma	of	 aggressive	 chemotherapy	was	
challenged	 in	a	series	of	experiments	using	 rodent	malaria	parasites	
which	 showed	 that	more	 prudent	 drug	 dosages	 better	 prevent	 the	
evolution	of	 resistance,	while	 still	 providing	clinical	benefit	 (Huijben	
et	al.,	2010,	2013;	Read,	Day,	&	Huijben,	2011;	Wargo,	Huijben,	de	
Roode,	Shepherd,	&	Read,	2007).	The	rationale	here	is	that	resistant	
424  |     HUIJBEN aNd PaaIJMaNS
mutants	 are	 competing	with	 intrinsically	 fitter	 susceptible	wild-	type	
parasites.	This	competition	slows,	or	even	 reverts,	 the	spread	of	 re-
sistance	 in	 the	 absence	 of	 treatment.	 Aggressive	 treatment	 rapidly	
removes	this	suppressive	competition	and	allows	for	the	proliferation	
of	resistant	mutants,	arguing	for	the	use	of	the	lowest	clinically	use-







































4  | WILL DIFFERENT TOOLS FACE THE 
SAME PROBLEMS?







Ignell,	Logan,	&	Field,	2010).	Other	 tools	 such	as	endectocides	 (not	
yet	reported	in	Anopheles,	but	shown	for	Onchocerca volvulus	(Osei-	
Atweneboana	 et	al.,	 2011))	 and	 genetically	 modified	 mosquitoes	
(Unckless,	Clark,	&	Messer,	2017)	are	also	prone	to	the	development	
of	resistance.	In	addition,	we	need	to	realize	that	resistance	may	not	
necessarily	 occur	 through	 genetic	 changes,	 but	 may	 be	 a	 result	 of	
changes	in	mosquito	behaviour.
If	we	are	to	target	the	parasites	with	a	vaccine,	we	have	to	realize	






5  | SHOULD WE EXPECT SOME 
UNFORESEEN INTELLIGENCE IN 
MOSQUITOES AND PARASITES?
Before	we	conclude	this	review,	we	would	like	to	hypothesize	about	
other,	 yet	 unidentified,	 evolutionary	 consequences	 of	 the	 way	 we	
currently	target	mosquito	and	parasite	populations,	particularly	in	the	
face	of	malaria	elimination	strategies.















With	 the	 envisioned	 improvements	 of	 the	 current	 surveillance	
systems	and	the	absence	of	mass	drug	adminstration,	will	we	select	
for	 parasites	 that	 hide	 and	 survive	 in	 asymptomatic	 individuals	 (i.e.,	
infected	 individuals	who	show	no	symptoms	or	are	below	detection	
threshold),	 as	 we	 will	 only	 detect	 and	 treat	 the	 symptomatic	 indi-
viduals?	Hence,	 could	we	 be	 selecting	 for	 less	 virulent	 parasites	 to	
avoid	 detection	 (but	 see	 Birget,	 Greischar,	 Reece,	 &	Mideo,	 2017)?	
There	 is	a	clear	need	 for	a	better	understanding	of	 the	 role	of	 sub-
microscopic	 infections	 in	 the	 epidemiology	 of	 resistant	 mutants	
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(Abdul-	Ghani,	Mahdy,	Beier,	&	Basco,	2017)	as	well	as	the	mosquito	
vector	 (Mharakurwa	 et	al.,	 2011).	 In	 addition,	when	we	 bring	more	
drugs	onto	the	market	with	a	long	prophylactic	effect,	could	we	select	



















to	 human	 hosts	 (Smallegange	 et	al.,	 2013).	With	 this	 phenotype	 al-
ready	 observed	 in	 the	 population,	 the	 potential	 for	 selection	 on	 in-
creased	host	manipulation	is	present	(discussed	by	Lefevre	et	al.	2017).
Further	 potential	 secondary	 evolutionary	 adaptations	 may	 be	
parasites	adapting	to	insecticide-	resistant	mosquitoes	with	a	shorter	
lifespan	by	evolving	faster	development	rates,	or	insecticide-	resistant	
mosquitoes	 having	 a	 selective	 advantage	 in	 areas	 of	 high	 parasite	
pressure	if	the	survival	cost	associated	with	parasite	burden	is	smaller	
in	 insecticide-	resistant	 mosquitoes	 (Alout	 et	al.,	 2016;	 Rivero	 et	al.,	
2010).	 Equally	 unknown	 is	 the	 role	 of	 the	 mosquito	 vector	 in	 the	
spread	 of	 antimalarial	 resistance	with	 markedly	 different	 resistance	














alternative	 treatment	 available	 to	 replace	 them,	 which	 is	 alarming,	
especially	 if	ACT	 resistance	will	 jump	 to	or	 emerge	 in	 sub-	Saharan	
Africa.	 The	 situation	 for	 the	 vector	 control	 landscape	 is	 not	 more	





catastrophe”	 (Hemingway,	 Ranson	 et	al.,	 2016).	 A	 greater	 under-
standing	of	the	general	evolutionary	principles	that	are	at	the	core	of	
emerging	resistance	is	urgently	needed,	and	will	allow	us	to	develop	
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